Fair Value Measurements (Tables)

9 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Schedule Of Fair Value Hierarchy, Assets (Liabilities) Carried At Fair Value

(in millions)	Level 1		Level 2			Level 3			Total
Contingent consideration	$	—	$	—		$	(7.3	)	$	(7.3	)
Interest rate derivative instruments	—		0.7			—			0.7
Foreign currency exchange contracts	—		(5.6		)	—			(5.6		)
Total	$	—	$	(4.9	)	$	(7.3	)	$	(12.2	)

(in millions)	Level 1		Level 2			Level 3			Total
Contingent consideration	$	—	$	—		$	(4.7	)	$	(4.7	)
Interest rate derivative instruments	—		(0.7		)	—			(0.7		)
Foreign currency exchange contracts	—		(0.5		)	—			(0.5		)
Total	$	—	$	(1.2	)	$	(4.7	)	$	(5.9	)

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]

The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:

	Health Advances
Unobservable Input	Range
Risk free rate	1%
Revenue Volatility	25%
Projected period of payment	Approximately 3 years

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table provides a summary of the change in our valuation of the fair value of the contingent consideration, which was determined by Level 3 inputs:

(in millions)	Fair Value
Balance at June 30, 2015	$	7.3
Additions of contingent consideration due to Health Advances acquisition	4.5
Change in fair value of contingent consideration	8.2
Payment of contingent consideration	(14.1		)
Effect of changes in exchange rates used for translation	(1.2		)
Balance at March 31, 2016	$	4.7